Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Makes Second Round of Investments in Genomics Startups Through Accelerator Program

NEW YORK (GenomeWeb) – Illumina has made a second round of investments in genomics start-up companies through its accelerator programs, the company said today.

The three startups are focused on healthcare, agriculture, and winemaking. PathoGn is a California-based infectious disease platform company using genomics and machine learning to build diagnostics and forecasting products for agriculture applications. Biome Makers was founded by The Wine Guys in Castile and Leon, Spain and will use genomics as quality control in wine making. Oregon-based Urology Diagnostics is developing noninvasive diagnostics based on sequencing urine to screen for and monitor cancer.

The three startups will each receive a seed investment, a subscription to Illumina's NextBio translational genomics database, access to match funding through the $40 million Illumina Accelerator Boost Capital, and sequencing systems and reagents. The companies will also gain access to lab space in the San Francisco Bay area during the six-month funding cycle.

Illumina launched its accelerator program last year. In July, the first three companies — Encoded Genomics, EpiBiome, and Xcell Biosciences — graduated from the program.

In a statement, Amanda Cashin, who leads Illumina Accelerator, said that Illumina's goal is to help the startups "create significant value, generate terabases of sequencing data, and advance their genomics applications."

Illumina plans accept startups to its accelerator program twice per year. The next set of applications are due Sept. 1.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.